PARIS and MOUNTAIN VIEW, Calif., Aug. 31, 2015 /PRNewswire/ -- Sanofi
(NYSE: SNY; EURONEXT: SAN) and the life sciences team at Google
announced today that they are collaborating to improve care and
outcomes for people with type 1 and type 2 diabetes. The
collaboration will pair Sanofi's leadership in diabetes
treatments and devices with Google's expertise in analytics,
miniaturized electronics and low power chip design. The companies
will explore how to improve diabetes care by developing new tools
that bring together many of the previously siloed pieces of
diabetes management and enable new kinds of interventions. This
includes health indicators such as blood glucose and hemoglobin A1c
levels, patient-reported information, medication regimens and
sensor devices.
Sanofi and the life sciences team at Google will combine their
respective expertise in science and technology to work on better
ways to collect, analyze and understand multiple sources of
information impacting diabetes. The hope is that it will be easier
for patients to successfully manage their diabetes, which would
reduce the risk of complications, improve outcomes and ultimately
lower costs.
"As a global leader in diabetes care, we have both an
obligation and a commitment to provide integrated solutions for
people living with diabetes," said Olivier Brandicourt, MD, Chief Executive
Officer, Sanofi. "This initiative combines Sanofi's strength and
knowledge in diabetes with Google's leadership in technology and
analytics to create a first-of-its-kind initiative with the
potential to transform diabetes care."
"With new technologies emerging to provide a more continuous
and real-time view of a patient's health, we can see the promise
for more proactive and effective ways to control diabetes,"
said Andy Conrad, CEO of the life
sciences team at Google. "Together with Sanofi, we believe
diabetes management can be simpler and more convenient, which may
help patients achieve an improved quality of life."
"We have built expertise in providing holistic, integrated
solutions that combine medicines, devices, technologies and
services," said Pascale Witz,
Executive Vice President, Sanofi, who will lead the Global Diabetes
and Cardiovascular Care Business Unit in the company's new
organizational structure. "The life sciences team at Google can
help us improve the patient experience, outcomes and manage
healthcare costs more effectively."
"We are experiencing a worldwide pandemic of diabetes, and
it's very encouraging to see healthcare and technology innovators
step up to the challenge of providing cutting edge tools and care
advancing technologies to help people with diabetes manage their
disease, 24/7," said John L. Brooks,
III, President and CEO of Joslin Diabetes Center, which is a
partner to the collaboration. "Technology, sensors, analytics,
and digital solutions will revolutionize how blood sugars are
managed, which will deliver improved quality of life, lowering the
risk of complications and reducing the costs and barriers
associated with diabetes care. Ultimately, I truly hope we're able
to turn the Joslin Diabetes Center into a museum."
About Diabetes
Diabetes mellitus, or simply diabetes, is a chronic disease that
occurs when the pancreas is no longer able to make insulin, or when
the body cannot make good use of the insulin it produces. Insulin
is a hormone made by the pancreas that acts like a key to let
glucose from the food we eat pass from the blood stream into the
cells in the body to produce energy. All carbohydrate foods are
broken down into glucose in the blood. Insulin helps glucose get
into the cells.[1]
Not being able to produce insulin or use it effectively leads to
raised glucose levels in the blood (known as hyperglycemia). Over
the long-term high glucose levels are associated with damage to the
body and failure of various organs and
tissues.[2]
The latest edition IDF Diabetes Atlas, published on World
Diabetes Day, estimates that people living with diabetes will surge
from 382 million to 592 million people by
2035.[3]
About Sanofi Diabetes
Sanofi strives to help people manage the complex challenge of
diabetes by delivering innovative, integrated and personalized
solutions. Driven by valuable insights that come from listening to
and engaging with people living with diabetes, the Company is
forming partnerships to offer diagnostics, therapies, services, and
devices including blood glucose monitoring systems. Sanofi markets
injectable, inhaled and oral medications for people with type 1 or
type 2 diabetes.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs.
Sanofi has core strengths in diabetes solutions, human vaccines,
innovative drugs, consumer healthcare, emerging markets, animal
health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
About the life sciences team at Google
The life sciences team at Google is focused on helping to move
health care from reactive to proactive. Combining expertise
from the fields of biology, chemistry, physics, medicine,
electrical engineering, computer science, we're developing new
technology tools for physicians that can integrate easily into
daily life and help transform the detection, prevention, and
management of disease. Current projects in development include a
smart contact lens with miniaturized glucose sensor; a
nanodiagnostics platform to help with early detection of disease;
and Liftware utensils for people with tremor.
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These statements include projections and
estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product
development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words "expects", "anticipates", "believes", "intends",
"estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the absence of guarantee that the
product candidates if approved will be commercially successful, the
future approval and commercial success of therapeutic alternatives,
the Group's ability to benefit from external growth opportunities,
trends in exchange rates and prevailing interest rates, the impact
of cost containment policies and subsequent changes thereto, the
average number of shares outstanding as well as those discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under "Risk Factors" and "Cautionary
Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on Form 20-F for the year ended December 31, 2014. Other than as required by
applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.
Contacts:
Sanofi
Media
Relations
Mary Kathryn
Steel
Tel.: + 1 (908)
989-0726
USMediaRelations@Sanofi.com
|
Investor
Relations
Sebastien
Martel
Tel.: + (33) 1 53 77
45 45
ir@sanofi.com
|
Google Life
Sciences
press@google.com
|
|
[1] IDF
http://www.idf.org/about-diabetes
[2] IDF
http://www.idf.org/about-diabetes
[3] IDF
http://www.idf.org/sites/default/files/Global_WDD_Final.pdf
Logo -
http://photos.prnewswire.com/prnh/20110616/NY20158LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sanofi-to-collaborate-with-google-life-sciences-to-improve-diabetes-health-outcomes-300135001.html
SOURCE Sanofi